Eurordis - Rare Disease Europe

Webinar: Streamlining the ATMP Development Pathway in the EU

The aim of our Join4ATMP webinars will be to showcase the challenges in the ATMP development pathway, from pre-clinical research, GMP manufacturing through to clinical translation, market approval, price reimbursement, and ultimately patient access. 

Patient involvement in the ATMP development is critical to ensure the identification of meaning outcomes and endpoints that can demonstrate clinical efficiency, patient safety and therapeutic value. 

These webinars will start the engagement with patient community and warm up the discussion on the hurdles of the existing ATMP development pathway, specifically to: 

• Identify the existing changes and hurdles for ATMP research and development pathway.  

• Chart the solutions to speed up and make leaner the development pathway to cultivating a viable and healthy pipeline of new ATMPs. 

• Explore the opportunity of JOIN4ATMP to identify the key huddles and barriers and co-design the recommendations that can strengthen the ATMP eco-system in Europe. 

The webinar will focus on the challenges from navigating the regulatory pathway to access, using a rare condition as a used case.

The session will be chaired by Matt Bolz-Johnson, ATMP & Mental Health Advisor, EURORDIS.

Panelists at the webinar will include:  

• Maria Pia Cicalese, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET).
• Lerie Sollis, International Patient Organisation for Primary Immunodeficiencies (IPOPI).
• Silva Martin Lluesma, Vall d’Hebron Institute of Oncology & CEU San Pablo University.

The subsequent webinar of this series will take place on 12 May, focusing on the topic of Streamlining the CAR-T Development Pathway in the EU.

? Webinar One: Streamlining the ATMP Development Pathway in the EU
➡️ Register now!
?️ 10 April 2025
⏰ 12:00 to 13:30 CET